

In the Claims:

Please amend claims 15, 17-20, 23 and 26-28 as follows:

15. (Amended) A method of treating Type I diabetes mellitus in a mammal comprising administering to said mammal in a suitable regimen an effective amount of an insulin and an effective amount of a glucagon-like peptide 1(7-36) amide agonist, wherein said glucagon-like peptide 1(7-36) amide agonist is administered by a non-intravenous route.

17. (Amended) A method according to claim 16 wherein said insulin and said [peptide] glucagon-like peptide 1(7-36) amide agonist are administered to the human at a selected time prior to ingestion of a meal.

18. (Amended) A method according to any of claims 15-17 or 46 wherein said glucagon-like peptide 1(7-36) amide agonist is glucagon-like peptide 1(7-37).

19. (Amended) A method according to any of claims 15-17 or 46 wherein said glucagon-like peptide 1(7-36) amide agonist is glucagon-like peptide 1(7-36) amide.

20. (Amended) A method according to any of claims 15-17 or 46 wherein said glucagon-like peptide 1(7-36) amide agonist is administered subcutaneously.

23. (Amended) A method of treating Type I diabetes mellitus in a mammal comprising administering to said mammal in a suitable regimen an effective amount of a glucagon-like peptide 1(7-36) amide agonist, wherein said glucagon-like peptide 1(7-36) amide agonist is administered by a non-intravenous route.

26. (Amended) A method according to any of claims 23-25 or 47 wherein said glucagon-like peptide 1(7-36) amide agonist is glucagon-like peptide 1(7-37).

27. (Amended) A method according to any of claims 23-25 or 47 wherein said glucagon-like peptide 1(7-36) amide agonist is glucagon-like peptide 1(7-36) amide.

28. (Amended) A method according to any of claims 23-25 or 47 wherein said glucagon-like peptide 1(7-36) amide agonist is administered subcutaneously.

Please cancel claims 31-37 without prejudice.

Please add new claims 38-47, as follows:

38. A method of treating postprandial hyperglycemia in a mammal having Type 1 diabetes comprising administering to said mammal in a suitable regimen an effective amount of an insulin and an effective amount of a glucagon-like peptide 1(7-36) amide agonist, wherein said glucagon-like peptide

1(7-36) amide agonist is administered by a non-intravenous route.

39. A method according to claim 38 wherein said glucagon-like peptide 1(7-36) amide agonist is administered orally, nasally or subcutaneously.

40. A method according to claim 39 wherein said mammal is human.

41. A method according to claim 39 wherein said insulin and said peptide are administered to the human at a selected time prior to ingestion of a meal.

42. A method according to any of claims 38-41 wherein said glucagon-like peptide 1(7-36) amide agonist is glucagon-like peptide 1(7-37).

43. A method according to any of claims 38-41 wherein said glucagon-like peptide 1(7-36) amide agonist is glucagon-like peptide 1(7-36) amide.

44. A method according to any of claims 38-41 wherein said glucagon-like peptide 1(7-36) amide agonist is administered subcutaneously.

45. A method according to claim 42 wherein said glucagon-like peptide 1(7-37) is administered subcutaneously.

46. A method according to claim 43 wherein said glucagon-like peptide 1(7-36) amide is administered subcutaneously.

46. A method according to claim 15 wherein said glucagon-like peptide (7-36) amide agonist is administered orally, nasally or subcutaneously.

47. A method according to claim 23 wherein said glucagon-like peptide (7-36) amide agonist is administered orally, nasally or subcutaneously.

REMARKS

Claims 15-37 are pending in the present application. In this Response, claims 15, 20, 23 and 26-28 are amended to provide further clarity with regard to the manner of administration, claim 17 is also amended to provide further clarity, claims 31-37 are cancelled without prejudice to file a continuing application directed to the subject matter of these claims, and new claims 38-47 are added. Support for the amendments to claims 15, 18-20, 23 and 26-28 is found throughout the specification and claims as originally filed, for example, at pages 8, lines 9-14 of the specification and in Examples 4-6. Support for new claims 38-45 is found, for example, at pages 5-7 of the specification, particularly, page 7, lines 12-15, and in Examples 5 and 6. Support for new claims 46 and 47 is found, for